Video

Screening for Pancreatic Cancer in High-Risk Individuals

For High-Definition, Click

Effective screening for pancreatic cancer remains heavily a research question. At this time, no major professional group recommends routine population-based screening nor has any screening test been shown to lower the risk of death from the disease.

One challenge facing screening for pancreatic cancer is a lack of a proven selection process to determine which patients constitute the appropriate high-risk group to target. As a result, it is unclear exactly who needs to be to be screened, at what age to start, or at what intervals, Philip Philip, MD, PhD, explains.

What to do with the findings is also often uncertain, recognizing the potential for an invasive intervention that may not be necessary in an otherwise healthy patient following a false positive, Philip notes. However, major academic centers have screening programs and are collaborating to answer questions regarding the best approach.

For these reasons, population-based screening for pancreatic cancer is not something to expect in the near future. However, there are several small groups of people known to be at higher risk, such as those with positive family history, Lynch Syndrome, or BRCA mutations, explains Eileen O’Reilly, MD. Noninvasive imaging tools can be used for early detection in these patients. Some screening programs have incorporated using alternating endoscopic ultrasound and MRI in the very high-risk population, since exposing these patients to radiation with routine CT scans is less desirable.

Related Videos
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.